Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837483 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
A Phase 3 study of Wiskott-Aldrich Syndrome, sponsored by Fondazione Telethon.
- Active
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT03837483 is a Phase 3 study of Wiskott-Aldrich Syndrome that is active but no longer recruiting, run by Fondazione Telethon. The registered enrollment target is 10 participants, below the 108-participant average among 4 other Wiskott-Aldrich Syndrome trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03837483, a Phase 3 study of Wiskott-Aldrich Syndrome, is active but no longer recruiting, sponsored by Fondazione Telethon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.
Conditions Studied
Interventions
- GENETIC OTL-103
Study Locations (2)
Georgia
- Children's Healthcare of Atlanta, Inc - Atlanta
Other
- Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET) - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-01-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03837483
The ClinicalTrials.gov registry entry for NCT03837483 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 4 other Wiskott-Aldrich Syndrome trials with a reported enrollment target (91% lower). The listed sponsor is Fondazione Telethon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wiskott-Aldrich Syndrome appearing as the primary indexed condition, and to 1 intervention - of which OTL-103 is the first listed.
NCT03837483 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Other.
Frequently Asked Questions
What is clinical trial NCT03837483 about?
NCT03837483 is a clinical study titled "A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome". This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103 Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation lentiviral vector.
What is the current status of trial NCT03837483?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2019-01-21. Estimated completion is 2027-09.
What conditions does trial NCT03837483 study?
This clinical trial studies the following conditions: Wiskott-Aldrich Syndrome.
What interventions are being tested in trial NCT03837483?
The interventions under investigation include: OTL-103 (GENETIC).
Who is sponsoring clinical trial NCT03837483?
This trial is sponsored by Fondazione Telethon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03837483 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wiskott-Aldrich Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
COMPLETED · Phase 3
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.